BI Asset Management Fondsmaeglerselskab A S Has $4.49 Million Stock Position in Boston Scientific Corporation $BSX

BI Asset Management Fondsmaeglerselskab A S lowered its position in Boston Scientific Corporation (NYSE:BSX) by 45.1% during the first quarter, HoldingsChannel.com reports. The firm owned 71,593 shares of the medical equipment provider’s stock after selling 58,923 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S’s holdings in Boston Scientific were worth $4,492,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. FWL Investment Management LLC acquired a new position in Boston Scientific in the second quarter worth approximately $26,000. Swiss RE Ltd. acquired a new stake in Boston Scientific in the fourth quarter valued at approximately $26,000. Garton & Associates Financial Advisors LLC acquired a new stake in Boston Scientific in the fourth quarter valued at approximately $26,000. Colonial Trust Co SC grew its position in Boston Scientific by 502.2% in the third quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 231 shares in the last quarter. Finally, Bangor Savings Bank grew its position in Boston Scientific by 94.7% in the fourth quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock worth $28,000 after acquiring an additional 142 shares in the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

BSX has been the topic of a number of recent research reports. Citigroup cut their price target on shares of Boston Scientific from $87.00 to $70.00 and set a “buy” rating on the stock in a report on Thursday, May 28th. Oppenheimer set a $90.00 price objective on shares of Boston Scientific in a report on Thursday, April 23rd. UBS Group lowered their target price on shares of Boston Scientific from $120.00 to $105.00 and set a “buy” rating on the stock in a research report on Tuesday, March 17th. Piper Sandler reiterated an “overweight” rating and set a $65.00 price target on shares of Boston Scientific in a research note on Friday, June 12th. Finally, Wall Street Zen downgraded Boston Scientific from a “buy” rating to a “hold” rating in a research note on Saturday, March 28th. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $85.08.

Insider Transactions at Boston Scientific

In other news, Director Edward J. Ludwig acquired 3,580 shares of the stock in a transaction dated Wednesday, May 20th. The shares were acquired at an average cost of $56.68 per share, for a total transaction of $202,914.40. Following the completion of the transaction, the director owned 25,359 shares in the company, valued at approximately $1,437,348.12. This trade represents a 16.44% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director David C. Habiger bought 2,250 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The stock was purchased at an average price of $55.92 per share, with a total value of $125,820.00. Following the completion of the purchase, the director directly owned 13,878 shares of the company’s stock, valued at $776,057.76. This represents a 19.35% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders have bought 9,800 shares of company stock valued at $554,012. 0.34% of the stock is owned by corporate insiders.

Boston Scientific Stock Down 2.2%

Shares of BSX opened at $44.30 on Tuesday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. The company has a 50-day simple moving average of $54.37 and a 200-day simple moving average of $72.44. Boston Scientific Corporation has a 52 week low of $44.05 and a 52 week high of $109.50. The firm has a market capitalization of $65.84 billion, a P/E ratio of 18.53, a P/E/G ratio of 0.87 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The business had revenue of $5.20 billion for the quarter, compared to the consensus estimate of $5.19 billion. During the same period last year, the business earned $0.75 earnings per share. The firm’s revenue for the quarter was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, equities research analysts expect that Boston Scientific Corporation will post 3.36 earnings per share for the current year.

Boston Scientific declared that its board has approved a share repurchase program on Monday, May 18th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical equipment provider to repurchase up to 6.4% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s board believes its shares are undervalued.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.